$100B+ Market Target for Sub-Penny Play IMMB; HIV/AIDS,
Hepatitis C, Cancer Treatments in the Works

Hi and good afternoon,

Tonight we are looking at a play with an extremely low float (only 9Mln) that is currently sitting at just 0045. I don’t know if we’ve ever covered anything like this before, so let’s get to it:

Ebola has taken the nation and world by storm over the last month or two. Turn on you TV; it’s what is being talked about. Liberal channels, conservative channels… it doesn’t matter. It’s the hottest topic of them all.

And why not? Ebola is terrifying. I’m sure by now you’ve taken the time to read or watch one of those “Get the Facts about Ebola” webpages: 80pct mortality rate, if treatment methods don’t change cases could reach 1.4Mln by January of next year, the current Ebola epidemic is 14 times larger than the bigger than the last largest outbreak, over 54pct of health care workers that became infected have died despite having full access to treatment.

As I said, it’s frightening to think about.

This new Ebola scare has translated into a birth of monumental breakouts for many biotech companies… a virtual overnight renaissance… and it’s still going on:

Generex went from .0161 to .0388, a run of over 140pct
Aethlon went from .1025 to .3070, a run of over 199pct
Ibio went from .24 to 3.48, a run of 1350pct
Alpha Pro Tech went from 2.03 to 10.73, a run of over 428pct
Tekmira went from 8.86 to 29.93, a run of over 237pct

The list goes on. Some smaller biotech companies saw short-term jumps in the multiple thousands of percent.

Tonight we’re profiling a small biotech company that has already reached some impressive milestones and has extensive experiments in viral treatments and other immuno related disorders. In fact, when you see the numbers on this company you may feel the same immediate excitement that I felt the first time I saw them:

The low float (as stated by otcmarkets . com)
Its current level of only 0045 (less than half a cent)
The multitude of immune-therapeutic treatments (one of which has successfully completed Phase I and Phase II field trials)

It’s extraordinary!

These are the type of numbers that I love to see (but rarely do) and with such low levels even just a slight increase in activity could lead to some out-of-this-world percentage increases.

This drug development company is working on solving some of the biggest medical issues of our time… in particular HIV/AIDS, Cancer and other immuno related disorders.

Today's Profile is:
Immunotech Laboratories, Inc. (IMMB)

Company Website

IMMB Quote

Immunotech is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. The Company strives to become a leader in immune-therapeutic treatment and prevention of HIV/AIDS, Cancer and other immune related disorders.

This Company is the “Real Deal”, in case you haven’t seen their recent news; IMMB recently announced the successful completion of Phase I and Phase II field trials in Bulgaria of the Company’s HIV/AIDS and Hepatitis C virus treatment (ITV-1 Treatment) and has begun negotiations for sites in Macedonia and Serbia for Phase III testing on human patients.

Take a look at the following excerpt for the most recent company press release:

“The successful completion of Phase III clinical study testing would enable Immunotech Laboratories (IMMB) to move forward using the Phase I, II, & III clinical trial results, for the FDA application pertaining to legal use of the treatment for HIV/AIDS and Hepatitis “C” patients in the USA.”

Immunotech’s flagship compound is ITV-1 (Immune Therapeutic Vaccine-1). ITV-1 is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS.

IPF has already shown great promise in treating HIV infections while overcoming the cost, toxicity, compliance and drug resistance of existing treatments. The results of four non-US experimental trials on 200 patients show the action and effectiveness of the vaccine. Immunological results are:

Increase in percentages and numbers of CD8 and CCR5 positive cells in the treated patients.
Significant increase in CD8+, CD38+ cells in the treated patients.
Significant increase in both CD4+ iNFg, secreting cells in the treated patients.

While ITV -1 is IMMB’s flagship compound for the treatment of HIV/AIDS, the Company also has other compounds in their pipeline which extends to Prenatal and Pediatric HIV, as well as the development of an HIV vaccine.

IPF has also demonstrated advantages over traditional HIV treatments including:

Significantly fewer and milder side effects
Minimal toxicity
Does not cause viral mutation
Requires only a short treatment cycle
Enhances the immune system and enhances quality of life
Cost effectiveness
Simple and short treatment modality without compliance issues
Treatment of drug resistant patients

In addition to treating HIV/AIDS patients with IPF, it has also been found useful for detecting and treating numerous types of cancer and hepatitis.

The Company recently announced that they have entered negotiations to pursue the development of market opportunities and Clinical Testing for the Company’s HIV/AIDS and Hepatitis C virus treatment in Africa. There are an estimated 30M people in Africa alone who suffer from HIV/AIDS.

Now while that’s half a world away for many of us, viral and immune disorders are also an ever-present staple in our society as well. Just look at the uprising over Ebola.

What does that mean? You ask. How does that translate into market share, size, etc? The numbers are staggering:

The global market for HIV therapeutics and diagnostics is expected to grow to 18.2Bln in 2013.
Analysts forecast the Global HIV/AIDS Testing market will grow at a CAGR of 5.4% to 2018.
Research from Datamonitor Healthcare has revealed that the Hepatitis C market is forecast to grow to 230%.
GMR Data forecasts that the global cancer treatment market will reach 143.7B by 2023.
The market for cancer immunotherapy in major world markets is projected to grow to nearly 9Bln by 2022.
In 2010, the global market for drugs for the treatment of immune disease was estimated at approximately 72.2Bln.

At just 0045 even a slight move could translate to massive percentages.

IMMB seems to be the “real deal” and has a LOT going for them at the moment.

Considering the current Ebola driven environment and the recent biotech rush IMMB could be finding itself in the right place at the right time; so get started on researching this exciting biotech company right away.

Remember, we always encourage you to do further research. Never take our word for it, read our disclaimer to see why, and of course always consult a professional.

Just because a situation looks great things can still go wrong and often do. Be smart and protect yourself.

Enjoy your afternoon,
NewPowerAlert Team